Literature DB >> 3084170

Intralipid disappearance in critically ill patients.

A Lindh, M Lindholm, S Rössner.   

Abstract

Intralipid elimination patterns were compared in 25 healthy controls, 12 patients recovering from uncomplicated cholecystectomy, and 25 critically ill patients. The intravenous fat tolerance test revealed a similar fractional removal rate (k2) in healthy controls and critically ill patients, but k2 was increased in cholecystectomy patients. The concentration of cross-reactive protein (CRP) correlated positively to the concentration of total triglyceride and low-density lipoprotein-triglyceride, and negatively to low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol. The extrapolated zero-time concentration of Intralipid in the critically ill patients was only one-third of the value in healthy controls. After this initial loss, however, Intralipid was removed from the circulation after first-order kinetics. These low concentrations of Intralipid were not correlated with concentrations of CRP. Possible explanations for this phenomenon include a change in the configuration of the lipid particles, the so-called creaming phenomenon, and/or immediate and substantial uptake of the emulsion by certain organs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084170     DOI: 10.1097/00003246-198605000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

1.  Adrenal-exhaustion syndrome in patients with liver disease.

Authors:  Paul E Marik
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

2.  Hypolipidemia: a word of caution.

Authors:  Rr Elmehdawi
Journal:  Libyan J Med       Date:  2008-06-01       Impact factor: 1.657

3.  Following severe injury, hypocholesterolemia improves with convalescence but persists with organ failure or onset of infection.

Authors:  C Michael Dunham; Michael H Fealk; Wilbur E Sever
Journal:  Crit Care       Date:  2003-10-01       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.